Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Independent medical education

Video module

This activity is supported by an educational grant from Lilly.

On-demand webcast

Advances in prostate cancer treatment and prognosis

This independent medical education meeting has been funded by Astellas.

New additions to the Adis Journal Club – August update

Browse August's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

Medical education

Virtual simulations

This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

Independent medical education

Digital treatment map for ALK- and ROS1-mutated NSCLC

This independent content was supported by an educational grant from Pfizer.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Breast cancer

IV drip close up

21-07-2022 | Breast cancer | News

KEYNOTE-355 shows OS benefit with pembrolizumab–chemo in advanced TNBC

Adding pembrolizumab to chemotherapy significantly improves the overall survival of people with advanced triple-negative breast cancer and a tumoral PD-L1 combined positive score of at least 10, demonstrate phase 3 trial data.

  • » This activity is supported by an educational grant from Lilly.

IN FOCUS | Lung & thoracic cancers

IV drip_patient's hand

09-08-2022 | WCLC 2022 | Conference coverage | News

NADIM II: Adding nivolumab to neoadjuvant chemo improves stage III NSCLC survival

The addition of nivolumab to neoadjuvant chemotherapy significantly improves the progression-free survival and overall survival of individuals with resectable stage IIIA–B non-small-cell lung cancer, suggest data from NADIM II.

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

IN FOCUS | Genitourinary cancers

Tablet with emojis

26-07-2022 | Renal cell carcinoma | News

KEYNOTE-426 QoL data further support pembrolizumab–axitinib in RCC

Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.

  • » This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

IN FOCUS | COVID-19 & cancer

abstract world map

11-07-2022 | COVID-19 | News

Cancer screening declined globally during COVID-19 pandemic

A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Podcasts

Interviews with clinical experts on cancer patient care